Getinge (OTCMKTS:GNGBY) Sets New 1-Year High – Here’s What Happened

Getinge (OTCMKTS:GNGBY) shares reached a new 52-week high on Monday. The stock traded as high as $28.03 and last traded at $28.03, with a volume of 408 shares changing hands. The stock had previously closed at $26.82.

Analyst Upgrades and Downgrades

GNGBY has been the topic of several analyst reports. Zacks Research downgraded Getinge from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 17th. Nordea Equity Research downgraded Getinge from a “buy” rating to a “hold” rating in a research note on Monday, August 31st. Pareto Securities downgraded Getinge from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 24th. Finally, UBS Group started coverage on shares of Getinge in a report on Wednesday, September 2nd. They issued a “hold” rating on the stock. Four analysts have rated the stock with a Hold rating. According to MarketBeat.com, the stock currently has an average rating of “Hold”.

Getinge Price Performance

The company has a market capitalization of $7.62 billion, a P/E ratio of 25.42 and a beta of 0.89. The firm’s fifty day moving average is $25.38 and its 200 day moving average is $22.61. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.74 and a current ratio of 1.31.

Getinge (OTCMKTS:GNGBY) last issued its earnings results on Wednesday, October 21st. The company reported $0.32 earnings per share (EPS) for the quarter. Getinge had a net margin of 8.20% and a return on equity of 11.55%. The firm had revenue of $875.58 million during the quarter. As a group, analysts predict that Getinge will post 1.36 earnings per share for the current fiscal year.

Getinge Company Profile

Getinge AB is a Sweden-based medical technology company that develops products and solutions for hospitals, healthcare providers and life sciences organizations. Its offerings are designed to support patient care, surgical procedures, infection prevention and the development and production of pharmaceuticals and other medical products.

The company’s portfolio includes equipment for intensive care and cardiovascular procedures, operating-room systems, surgical instruments, sterilization and disinfection solutions, and products used in laboratories and biopharmaceutical manufacturing.